Compare SRRK & CCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | CCC |
|---|---|---|
| Founded | 2012 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.5B |
| IPO Year | 2018 | 2020 |
| Metric | SRRK | CCC |
|---|---|---|
| Price | $48.62 | $7.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 18 | 8 |
| Target Price | ★ $70.44 | $7.75 |
| AVG Volume (30 Days) | 1.6M | ★ 35.4M |
| Earning Date | 11-10-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $1,057,001,000.00 |
| Revenue This Year | N/A | $10.10 |
| Revenue Next Year | $2,397.26 | $8.75 |
| P/E Ratio | ★ N/A | $70.09 |
| Revenue Growth | N/A | ★ 11.88 |
| 52 Week Low | $29.35 | $4.08 |
| 52 Week High | $61.76 | $8.68 |
| Indicator | SRRK | CCC |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 66.04 |
| Support Level | $45.82 | $5.72 |
| Resistance Level | $50.29 | $7.91 |
| Average True Range (ATR) | 2.31 | 0.03 |
| MACD | 1.10 | -0.03 |
| Stochastic Oscillator | 67.28 | 100.00 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies, and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, AI-enabled digital workflows. It operates in a single segment being Domestic segment, which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in the United States and China. The majority of the revenue is generated from the United States.